Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,732 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.
Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, Hullsiek KH, Balduin M, Jakobsen MR, Geretti AM, Thiebaut R, Ostergaard L, Masquelier B, Johnson JA, Miller MD, Kuritzkes DR. Li JZ, et al. Among authors: johnson ja. JAMA. 2011 Apr 6;305(13):1327-35. doi: 10.1001/jama.2011.375. JAMA. 2011. PMID: 21467286 Free PMC article. Review.
Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.
Geretti AM, Fox ZV, Booth CL, Smith CJ, Phillips AN, Johnson M, Li JF, Heneine W, Johnson JA. Geretti AM, et al. Among authors: johnson ja, johnson m. J Acquir Immune Defic Syndr. 2009 Dec;52(5):569-73. doi: 10.1097/QAI.0b013e3181ba11e8. J Acquir Immune Defic Syndr. 2009. PMID: 19779307
Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.
Li JZ, Paredes R, Ribaudo HJ, Kozal MJ, Svarovskaia ES, Johnson JA, Geretti AM, Metzner KJ, Jakobsen MR, Hullsiek KH, Ostergaard L, Miller MD, Kuritzkes DR. Li JZ, et al. Among authors: johnson ja. J Infect Dis. 2013 Mar 15;207(6):893-7. doi: 10.1093/infdis/jis925. Epub 2012 Dec 21. J Infect Dis. 2013. PMID: 23264671 Free PMC article.
Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Geretti AM, Fox Z, Johnson JA, Booth C, Lipscomb J, Stuyver LJ, Tachedjian G, Baxter J, Touloumi G, Lehmann C, Owen A, Phillips A; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Geretti AM, et al. Among authors: johnson ja. PLoS One. 2013 Jul 18;8(7):e69266. doi: 10.1371/journal.pone.0069266. Print 2013. PLoS One. 2013. PMID: 23874928 Free PMC article.
Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.
Geretti AM, Conibear T, Hill A, Johnson JA, Tambuyzer L, Thys K, Vingerhoets J, Van Delft Y; SENSE Study Group. Geretti AM, et al. Among authors: johnson ja. J Antimicrob Chemother. 2014 Apr;69(4):1090-7. doi: 10.1093/jac/dkt474. Epub 2013 Nov 27. J Antimicrob Chemother. 2014. PMID: 24284781 Clinical Trial.
Increased detection of the HIV-1 reverse transcriptase M184V mutation using mutation-specific minority assays in a UK surveillance study suggests evidence of unrecognized transmitted drug resistance.
Buckton AJ, Prabhu D, Motamed C, Harris RJ, Hill C, Murphy G, Parry JV, Johnson JA, Lowndes CM, Gill N, Pillay D, Cane PA. Buckton AJ, et al. Among authors: johnson ja. HIV Med. 2011 Apr;12(4):250-4. doi: 10.1111/j.1468-1293.2010.00882.x. Epub 2010 Oct 14. HIV Med. 2011. PMID: 21371237 Free article.
2,732 results